Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.4%

224 terminated/withdrawn out of 2652 trials

Success Rate

90.8%

+4.3% vs industry average

Late-Stage Pipeline

24%

633 trials in Phase 3/4

Results Transparency

53%

1169 of 2209 completed trials have results

Key Signals

90 recruiting1169 with results181 terminated43 withdrawn

Enrollment Performance

Analytics

Phase 1

1105(50.6%)

Phase 3

441(20.2%)

Phase 2

384(17.6%)

Phase 4

192(8.8%)

N/A

57(2.6%)

Early Phase 1

4(0.2%)

2183Total

Phase 1(1105)

Phase 3(441)

Phase 2(384)

Phase 4(192)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2652)

Showing 20 of 2652 trials

NCT07407348Phase 1Recruiting

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Role: lead

NCT06321302Phase 2Active Not Recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Role: lead

NCT04886804Phase 1Active Not Recruiting

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Role: lead

NCT07001475Phase 1Active Not Recruiting

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Role: lead

NCT07036523Phase 2Recruiting

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Role: lead

NCT06769048Phase 2Active Not Recruiting

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Role: lead

NCT06241560Phase 2Active Not Recruiting

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Role: lead

NCT07553429Phase 1Recruiting

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

Role: lead

NCT05238675Phase 2Completed

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Role: lead

NCT06013969Phase 4Active Not Recruiting

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Role: lead

NCT06872892Phase 3Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Role: lead

NCT07107945Phase 3Recruiting

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Role: lead

NCT07064473Phase 3Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Role: lead

NCT06139328Phase 2Terminated

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Role: lead

NCT06926660Phase 2Active Not Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Role: lead

NCT07727785Phase 1Not Yet Recruiting

A Study in Healthy People to Compare Two Tablet Formulations of Pramipexole

Role: lead

NCT07513207Phase 1Active Not Recruiting

A Study in Healthy People to Test How Vicadrostat Affects the Heart